MedWatch

Biotech company acquires former Novartis drug

Danish Oncology Venture has decided to execute its license to a potential drug developed by Novartis. The decision follows new positive, however not perfect, study data.

Foto: /ritzau/Lars Krabbe

Danish Oncology Venture has taken the opportunity to acquire the rights to develop and commercialize an unnamed Novartis-developed cancer drug. The drug is now co-owned by the Danish company, the parent company MPI, and a secret partner.

Oncology Venture made its decision after the analysis of 160 biopsies from a previous phase III study proved that the company’s Drug Response Predictor (DRP) technology can identify which patients will benefit from treatment with the cancer drug.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier